4.6 Review

How to Improve SBRT Outcomes in NSCLC: From Pre-Clinical Modeling to Successful Clinical Translation

Journal

CANCERS
Volume 14, Issue 7, Pages -

Publisher

MDPI
DOI: 10.3390/cancers14071705

Keywords

non-small-cell lung cancer; radiotherapy; SBRT; pre-clinical models

Categories

Funding

  1. INSERM
  2. SIRIC SOCRATE
  3. Canceropole IdF
  4. Fondation ARC pour la recherche sur le cancer
  5. Institut National du Cancer [INCa 2018-1-PL BIO-06-1]
  6. Fondation pour la Recherche Medicale [FRM DIC20161236437]

Ask authors/readers for more resources

Despite extensive research and clinical efforts, lung cancer remains the leading cause of cancer-related deaths. Stereotactic body radiotherapy (SBRT) has revolutionized the treatment of early-stage non-small-cell lung cancer (NSCLC), but further research is needed to understand drug resistance mechanisms and develop new treatments. Successful translation of preclinical research into clinical progress has been challenging thus far.
Simple Summary Despite major research and clinical efforts, lung cancer remains the leading cause of cancer-related death. Stereotactic body radiotherapy (SBRT) has emerged as a major treatment modality for lung cancer in the last decade. Additional research is needed to elucidate underlying mechanisms of resistance and to develop improved therapeutic strategies. Clinical progress relies on accurate preclinical modelling of human disease in order to yield clinically meaningful results; however, successful translation of pre-clinical research is still lagging behind. In this review, we summarize the major clinical developments of radiation therapy for non-small-cell lung cancer (NSCLC), and we discuss the pre-clinical research models at our disposal, highlighting ongoing translational challenges and future perspectives. Despite major research and clinical efforts, lung cancer remains the leading cause of cancer-related death. While the delivery of conformal radiotherapy and image guidance of stereotactic body radiotherapy (SBRT) have revolutionized the treatment of early-stage non-small-cell lung cancer (NSCLC), additional research is needed to elucidate underlying mechanisms of resistance and identify novel therapeutic combinations. Clinical progress relies on the successful translation of pre-clinical work, which so far has not always yielded expected results. Improved clinical modelling involves characterizing the preclinical models and selecting appropriate experimental designs that faithfully mimic precise clinical scenarios. Here, we review the current role of SBRT and the scope of pre-clinical armamentarium at our disposal to improve successful clinical translation of pre-clinical research in the radiation oncology of NSCLC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available